Be Biopharma Revenue and Competitors

Boston, MA USA

Location

$52M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Be Biopharma's estimated annual revenue is currently $20M per year.(i)
  • Be Biopharma's estimated revenue per employee is $204,031
  • Be Biopharma's total funding is $52M.

Employee Data

  • Be Biopharma has 98 Employees.(i)
  • Be Biopharma grew their employee count by -14% last year.

Be Biopharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VPReveal Email/Phone
3
Co-founder & VP, Strategy & OperationsReveal Email/Phone
4
VP Clinical Development OperationsReveal Email/Phone
5
VP, Business OperationsReveal Email/Phone
6
VP, External Manufacturing & Supply ChainReveal Email/Phone
7
Head ImmunologyReveal Email/Phone
8
SVP - Commercial and Franchise StrategyReveal Email/Phone
9
VP Non-Clinical DevelopmentReveal Email/Phone
10
SVP Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M1-50%N/AN/A
#3
$5.1M3322%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M2-60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A1110%N/AN/A
#10
$5.4M290%N/AN/A
Add Company

What Is Be Biopharma?

Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

keywords:N/A

$52M

Total Funding

98

Number of Employees

$20M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Be Biopharma News

2022-04-20 - Undeterred by gene therapy's struggles, a startup launches ...

Greenwald, however, is taking a long-term view, betting that interest in gene therapy research will be there once the downturn is over. “The...

2022-04-13 - Be Biopharma Closes $130M Financing

Be Biopharma, a Cambridge, MA-based developer of Engineered B Cell Medicines (BeCM), closed a $130m financing.

2022-04-06 - Be Bio Closes $130 Million Financing to Pioneer Engineered ...

--(BUSINESS WIRE)--Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM), today announced...

2020-10-26 - Be Biopharma Raises $52M in Series A Financing

Be Biopharma, a Cambridge, MA-based company developing B cells as medicines, raised $52m in Series A financing. The round was led by Atlas Venture and RA Capital Management joined by Alta Partners, Longwood Fund and Takeda Ventures. The company plans to use the funds to precisely engineer B ce ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18M983%N/A
#2
$24.9M98N/AN/A
#3
$31.7M9815%N/A
#4
$14.2M9827%N/A
#5
$17.6M982%N/A